News | August 13, 2021
JB Chemicals & Pharmaceuticals PAT at Rs. 118.9 cr for Q1 FY22
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Expect the international business including CDMO business to pick-up in the second half of the financial year
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
Move to increase affordability and accessibility for heart failure patients across the country
Subscribe To Our Newsletter & Stay Updated
